Steph & Co. Sells 27 Shares of argenx SE (NASDAQ:ARGX)

Steph & Co. cut its holdings in argenx SE (NASDAQ:ARGX) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 374 shares of the company’s stock after selling 27 shares during the period. Steph & Co.’s holdings in argenx were worth $230,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Stifel Financial Corp increased its position in argenx by 15.3% in the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after buying an additional 1,170 shares during the period. FMR LLC grew its stake in shares of argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares during the last quarter. Simplify Asset Management Inc. increased its position in argenx by 64.0% during the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock worth $1,311,000 after acquiring an additional 944 shares during the period. Perpetual Ltd acquired a new position in argenx during the 3rd quarter valued at $76,314,000. Finally, Logos Global Management LP acquired a new stake in argenx in the 2nd quarter worth $58,055,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $665.19 on Thursday. The business has a fifty day moving average of $617.93 and a 200-day moving average of $553.49. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The firm has a market cap of $40.16 billion, a PE ratio of -755.90 and a beta of 0.59.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the prior year, the firm earned ($1.25) EPS. On average, analysts anticipate that argenx SE will post 2.2 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ARGX. Citigroup upped their price objective on shares of argenx from $512.00 to $635.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Evercore ISI upped their price target on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Wedbush reissued an “outperform” rating and set a $655.00 price objective on shares of argenx in a report on Tuesday, December 3rd. Deutsche Bank Aktiengesellschaft lowered argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. Finally, JMP Securities boosted their price target on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.